ArticleCurrent treatment options in gastroenterology2016
Established and Emerging Treatment Options for Functional Heartburn and Chest Pain.
Article in Current treatment options in gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders.Current pharmaceutical biotechnology · 2024Pooled it
- Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.Current gastroenterology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementFunctional heartburn and functional chest pain of presumed esophageal origin are characterized by symptoms suggesting an esophageal origin, but negative work-up on routine investigations, including ruling out gastroesophageal reflux disease. Visceral hypersensitivity is a potentially unifying pathophysiological concept, thought to underlie these disorders. In addition, there is important overlap with other functional disorders and psychiatric co-morbidity. This review summarizes current concepts on definition, diagnosis, and treatment options for functional heartburn and functional chest pain of presumed esophageal origin. Antidepressants are frequently used in these conditions, where they are presumed to act as neuromodulators of visceral hypersensitivity. There is a need for high-quality trials evaluating the efficacy of antidepressants and more specific neuromodulators, such as pregabalin, in functional esophageal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.